New Members
![4 people wearing lab coats stand in a room talking and smiling.](https://www.tbdrugaccelerator.org/wp-content/uploads/2021/10/thisisengineering-raeng-JzdrZzZ50tA-unsplash-697x392.jpg)
The TBDA welcomed two new members after the October 2021 semi-annual meeting.
![](https://www.tbdrugaccelerator.org/wp-content/uploads/2021/10/ucsf-logo.jpeg)
The team specializes in data-driven pharmacokinetic-pharmacodynamic (PK/PD) modeling and simulation as a resource for improving global health. They apply quantitative, model-based principles of drug response and disease dynamics to optimize doses, dosing schedules, drug regimens and treatment durations, potentially bringing novel therapies to patients with unmet needs
![](https://www.tbdrugaccelerator.org/wp-content/uploads/2021/10/GatesMRI_Logo_Blk.png)
The team specializes in evaluating novel biomarkers of drug and drug regimen effect both pre-clinically and clinically, working with collaborators to improve and develop existing and newer animal models, evaluating drug candidates and targets to enhance treatment shortening for TB, and providing expertise and a potential development pathway for TBDA members’ drug candidates.